Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Decrease in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a large decrease in short interest in February. As of February 15th, there was short interest totalling 4,900 shares, a decrease of 52.9% from the January 31st total of 10,400 shares. Based on an average daily volume of 61,900 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, D. Boral Capital assumed coverage on Estrella Immunopharma in a report on Tuesday, February 18th. They issued a “buy” rating and a $16.00 price objective for the company.

Estrella Immunopharma Trading Up 7.3 %

Shares of ESLA traded up $0.07 during midday trading on Friday, reaching $1.03. The stock had a trading volume of 35,322 shares, compared to its average volume of 79,226. The company’s 50-day moving average is $1.17 and its 200 day moving average is $1.09. Estrella Immunopharma has a 12-month low of $0.63 and a 12-month high of $3.23. The company has a market capitalization of $37.26 million, a price-to-earnings ratio of -3.96 and a beta of 0.41.

Hedge Funds Weigh In On Estrella Immunopharma

An institutional investor recently raised its position in Estrella Immunopharma stock. Geode Capital Management LLC lifted its position in Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 93,418 shares of the company’s stock after purchasing an additional 16,862 shares during the quarter. Geode Capital Management LLC owned 0.26% of Estrella Immunopharma worth $106,000 at the end of the most recent quarter. 0.35% of the stock is currently owned by institutional investors and hedge funds.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.